Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1

Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative

(2012) Clifford E. Kashtan et al.   PEDIATRIC NEPHROLOGY

Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy

(2011) Oliver Gross et al.   KIDNEY INTERNATIONAL

Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial

(2011) N. J. A. Webb et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Glomerular pathology in Alport syndrome: a molecular perspective

(2011) Dominic Cosgrove   PEDIATRIC NEPHROLOGY

Cyclosporine A treatment in patients with Alport syndrome: a single-center experience

(2010) Laura Massella et al.   PEDIATRIC NEPHROLOGY

Addition of Spironolactone to Dual Blockade of Renin Angiotensin System Dramatically Reduces Severe Proteinuria in Renal Transplant Patients: An Uncontrolled Pilot Study at 6 Months

(2010) E. González Monte et al.   TRANSPLANTATION PROCEEDINGS

Treatment of Alport syndrome: beyond animal models

(2009) Oliver Gross et al.   KIDNEY INTERNATIONAL

Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease

(2009) Ibrahim Guney et al.   RENAL FAILURE

Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker

(2008) Yoshiyuki FURUMATSU et al.   HYPERTENSION RESEARCH